Minimal ablative margin (MAM) assessment with image fusion: an independent predictor for local tumor progression in hepatocellular carcinoma after stereotactic radiofrequency ablation

90Citations
Citations of this article
71Readers
Mendeley users who have this article in their library.

Abstract

Objectives: To assess the minimal ablative margin (MAM) by image fusion of intraprocedural pre- and post-ablation contrast-enhanced CT images and to evaluate if it can predict local tumor progression (LTP) independently. Furthermore, to determine a MAM with which a stereotactic radiofrequency ablation (SRFA) can be determined successful and therefore used as an intraprocedural tool to evaluate treatment success. Methods: A total of 110 patients (20 women, 90 men; mean age 63.7 ± 10.2) with 176 hepatocellular carcinomas were assessed by retrospective analysis of prospectively collected data. The MAM was determined through image fusion of intraprocedural pre- and post-ablation images using commercially available rigid imaging registration software. LTP was assessed in contrast-enhanced CTs or MR scans at 3–6-month intervals. Results: The MAM was the only significant independent predictor of LTP (p = 0.036). For each millimeter increase of the MAM, a 30% reduction of the relative risk for LTP was found (OR = 0.7, 95% CI 0.5–0.98, p = 0.036). No LTP was detected in lesions with a MAM > 5 mm. The overall LTP rate was 9 of 110 (8.2%) on a patient level and 10 of 173 (5.7%) on a lesion level. The median MAM was 3.4 (1.7–6.9) mm. The mean overall follow-up period was 26.0 ± 10.3 months. Conclusions: An immediate assessment of the minimal ablative margin (MAM) can be used as an intraprocedural tool to evaluate the treatment success in patients treated with stereotactic RFA. A MAM > 5 mm has to be achieved to consider an ablation as successful. Key Points: • An intraoperatively measured minimal ablative margin (MAM) > 5 mm correlates with complete remission. • MAM is the only significant independent predictor of LTP (OR = 0.7, 95% CI 0.5–0.98, p = 0.036) after stereotactic RFA of hepatocellular carcinoma. • Image fusion using commercially available rigid imaging registration software is possible, even though considerably complex. Therefore, improved (semi-)automatic fusion software is highly desirable.

References Powered by Scopus

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

6792Citations
N/AReaders
Get full text

Hepatocellular carcinoma

3986Citations
N/AReaders
Get full text

Hepatocellular carcinoma

3415Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Volumetric assessment of the periablational safety margin after thermal ablation of colorectal liver metastases

65Citations
N/AReaders
Get full text

Efficacy of fusion imaging for immediate post-ablation assessment of malignant liver neoplasms: A systematic review

37Citations
N/AReaders
Get full text

Diagnostic protocols in oncology: Workup and treatment planning. Part 2: Abbreviated MR protocol

34Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Laimer, G., Schullian, P., Jaschke, N., Putzer, D., Eberle, G., Alzaga, A., … Bale, R. (2020). Minimal ablative margin (MAM) assessment with image fusion: an independent predictor for local tumor progression in hepatocellular carcinoma after stereotactic radiofrequency ablation. European Radiology, 30(5), 2463–2472. https://doi.org/10.1007/s00330-019-06609-7

Readers over time

‘20‘21‘22‘23‘24‘2507142128

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 20

65%

Researcher 9

29%

Professor / Associate Prof. 2

6%

Readers' Discipline

Tooltip

Medicine and Dentistry 21

60%

Engineering 8

23%

Computer Science 4

11%

Mathematics 2

6%

Save time finding and organizing research with Mendeley

Sign up for free
0